CN104411684B - 苯氧基乙基哌啶化合物 - Google Patents

苯氧基乙基哌啶化合物 Download PDF

Info

Publication number
CN104411684B
CN104411684B CN201380034168.8A CN201380034168A CN104411684B CN 104411684 B CN104411684 B CN 104411684B CN 201380034168 A CN201380034168 A CN 201380034168A CN 104411684 B CN104411684 B CN 104411684B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
mmol
mixture
compounds
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380034168.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104411684A (zh
Inventor
M·A·席夫勒
J·S·约克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN104411684A publication Critical patent/CN104411684A/zh
Application granted granted Critical
Publication of CN104411684B publication Critical patent/CN104411684B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380034168.8A 2012-06-29 2013-06-20 苯氧基乙基哌啶化合物 Active CN104411684B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US61/665,951 2012-06-29
US201361779099P 2013-03-13 2013-03-13
US61/779,099 2013-03-13
PCT/US2013/046684 WO2014004229A1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Publications (2)

Publication Number Publication Date
CN104411684A CN104411684A (zh) 2015-03-11
CN104411684B true CN104411684B (zh) 2016-08-24

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380034168.8A Active CN104411684B (zh) 2012-06-29 2013-06-20 苯氧基乙基哌啶化合物

Country Status (42)

Country Link
US (2) US8962659B2 (show.php)
EP (1) EP2867207B1 (show.php)
JP (1) JP6127136B2 (show.php)
KR (1) KR101653476B1 (show.php)
CN (1) CN104411684B (show.php)
AP (1) AP2014008164A0 (show.php)
AR (1) AR091429A1 (show.php)
AU (1) AU2013280875B2 (show.php)
BR (1) BR112014031616B1 (show.php)
CA (1) CA2875569C (show.php)
CL (1) CL2014003535A1 (show.php)
CO (1) CO7151507A2 (show.php)
CR (1) CR20140553A (show.php)
CY (1) CY1119425T1 (show.php)
DK (1) DK2867207T3 (show.php)
DO (1) DOP2014000287A (show.php)
EA (1) EA024392B1 (show.php)
EC (1) ECSP14033267A (show.php)
ES (1) ES2644812T3 (show.php)
GT (1) GT201400288A (show.php)
HR (1) HRP20171515T1 (show.php)
HU (1) HUE034425T2 (show.php)
IL (1) IL236219A (show.php)
JO (1) JO3296B1 (show.php)
LT (1) LT2867207T (show.php)
MA (1) MA37686B1 (show.php)
ME (1) ME02840B (show.php)
MX (1) MX345324B (show.php)
MY (1) MY173878A (show.php)
NZ (1) NZ701933A (show.php)
PE (1) PE20150182A1 (show.php)
PH (1) PH12015500009B1 (show.php)
PL (1) PL2867207T3 (show.php)
PT (1) PT2867207T (show.php)
RS (1) RS56452B1 (show.php)
SG (1) SG11201408641UA (show.php)
SI (1) SI2867207T1 (show.php)
TN (1) TN2014000501A1 (show.php)
TW (1) TWI599561B (show.php)
UA (1) UA114325C2 (show.php)
WO (1) WO2014004229A1 (show.php)
ZA (1) ZA201408632B (show.php)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI636046B (zh) * 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
AU2014366361B2 (en) * 2013-12-17 2017-04-20 Eli Lilly And Company Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
HUE056382T2 (hu) 2017-05-18 2022-02-28 Idorsia Pharmaceuticals Ltd Pirimidin-származékok mint PGE2 receptor modulátorok
AU2018269666B2 (en) 2017-05-18 2022-02-03 Idorsia Pharmaceuticals Ltd Phenyl derivatives as PGE2 receptor modulators
AR111806A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
JP7253500B2 (ja) 2017-05-18 2023-04-06 イドーシア ファーマシューティカルズ リミテッド ピリミジン誘導体
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
CN111989311B (zh) * 2019-01-22 2022-03-22 凯复(苏州)生物医药有限公司 抑制pge2/ep4信号传导的化合物、其制备方法及其在医药上的应用
KR20230107228A (ko) 2020-11-13 2023-07-14 오노 야꾸힝 고교 가부시키가이샤 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021508A1 (en) * 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
CN1950333A (zh) * 2004-05-04 2007-04-18 辉瑞大药厂 取代的甲基芳基或杂芳基酰胺化合物
CN1950334A (zh) * 2004-05-04 2007-04-18 辉瑞有限公司 邻位取代的芳基或杂芳基酰胺化合物
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
CN102026961A (zh) * 2008-05-14 2011-04-20 安斯泰来制药株式会社 酰胺化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
JP2005531516A (ja) * 2002-03-18 2005-10-20 ファイザー・プロダクツ・インク 選択的ep4受容体アゴニストによる治療方法
CA2511255C (en) * 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
US20050105732A1 (en) * 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
CA2648729A1 (en) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
US7705035B2 (en) 2006-06-12 2010-04-27 Merck Frosst Canada Ltd. Indoline amide derivatives as EP4 receptor ligands
CN102149384B (zh) 2008-08-14 2014-08-20 南京奥昭生物科技有限公司 作为ep4受体拮抗剂的杂环酰胺衍生物
CA2789665C (en) 2010-02-22 2020-06-16 Raqualia Pharma Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
SI2619182T1 (sl) * 2010-09-21 2017-03-31 Eisai R&D Management Co., Ltd. Farmacevtski sestavek
ES2564353T3 (es) * 2011-07-04 2016-03-22 Rottapharm Biotech S.R.L. Derivados de aminas cíclicas como agonistas de los receptores EP4
CA2839116C (en) * 2011-07-04 2019-07-16 Rottapharm S.P.A. Cyclic amine derivatives as ep4 receptor antagonists
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021508A1 (en) * 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
CN1950333A (zh) * 2004-05-04 2007-04-18 辉瑞大药厂 取代的甲基芳基或杂芳基酰胺化合物
CN1950334A (zh) * 2004-05-04 2007-04-18 辉瑞有限公司 邻位取代的芳基或杂芳基酰胺化合物
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
CN102026961A (zh) * 2008-05-14 2011-04-20 安斯泰来制药株式会社 酰胺化合物

Also Published As

Publication number Publication date
AP2014008164A0 (en) 2014-12-31
AU2013280875B2 (en) 2015-09-24
KR101653476B1 (ko) 2016-09-01
ME02840B (me) 2018-01-20
MA37686B1 (fr) 2017-04-28
SI2867207T1 (sl) 2017-10-30
JP6127136B2 (ja) 2017-05-10
EP2867207B1 (en) 2017-08-09
HK1203937A1 (en) 2015-11-06
SG11201408641UA (en) 2015-01-29
IL236219A (en) 2017-12-31
DK2867207T3 (en) 2017-09-11
CL2014003535A1 (es) 2015-05-08
EA024392B1 (ru) 2016-09-30
EP2867207A1 (en) 2015-05-06
IL236219A0 (en) 2015-02-01
PT2867207T (pt) 2017-11-01
PH12015500009A1 (en) 2015-03-02
MY173878A (en) 2020-02-26
BR112014031616A2 (pt) 2017-06-27
US9402838B2 (en) 2016-08-02
PH12015500009B1 (en) 2020-10-09
PE20150182A1 (es) 2015-02-13
CA2875569C (en) 2016-04-19
MX2014015953A (es) 2015-07-17
UA114325C2 (uk) 2017-05-25
TN2014000501A1 (en) 2016-03-30
EA201492255A1 (ru) 2015-03-31
PL2867207T3 (pl) 2018-01-31
DOP2014000287A (es) 2015-01-31
TW201412717A (zh) 2014-04-01
JO3296B1 (ar) 2018-09-16
CR20140553A (es) 2015-02-04
HUE034425T2 (en) 2018-02-28
CO7151507A2 (es) 2014-12-29
US20150126555A1 (en) 2015-05-07
NZ701933A (en) 2017-01-27
WO2014004229A1 (en) 2014-01-03
CN104411684A (zh) 2015-03-11
ECSP14033267A (es) 2015-09-30
AR091429A1 (es) 2015-02-04
TWI599561B (zh) 2017-09-21
LT2867207T (lt) 2017-10-10
MX345324B (es) 2017-01-25
ES2644812T3 (es) 2017-11-30
RS56452B1 (sr) 2018-01-31
JP2015522018A (ja) 2015-08-03
CA2875569A1 (en) 2014-01-03
HRP20171515T1 (hr) 2017-11-17
GT201400288A (es) 2015-08-27
ZA201408632B (en) 2017-06-28
US20140005226A1 (en) 2014-01-02
MA37686A1 (fr) 2016-09-30
BR112014031616B1 (pt) 2022-06-21
CY1119425T1 (el) 2018-03-07
US8962659B2 (en) 2015-02-24
AU2013280875A1 (en) 2014-12-04
KR20150013893A (ko) 2015-02-05

Similar Documents

Publication Publication Date Title
CN104411684B (zh) 苯氧基乙基哌啶化合物
KR101634032B1 (ko) 디메틸-벤조산 화합물
CN105209438B (zh) 苯氧基乙基二氢‑1h‑异喹啉化合物
HK1203937B (en) Phenoxyethyl piperidine compounds
HK1203936B (en) Dimethyl-benzoic acid compounds useful for the treatment of inflammatory conditions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant